000 01323 a2200361 4500
005 20250517174617.0
264 0 _c20180530
008 201805s 0 0 eng d
022 _a2044-6055
024 7 _a10.1136/bmjopen-2016-015110
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLassman, Scott M
245 0 0 _aClinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
_h[electronic resource]
260 _bBMJ open
_cSep 2017
300 _ae015110 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAccess to Information
650 0 4 _aClinical Trials as Topic
650 0 4 _aCross-Sectional Studies
_xstatistics & numerical data
650 0 4 _aDisclosure
_xlegislation & jurisprudence
650 0 4 _aDrug Approval
650 0 4 _aDrug Industry
650 0 4 _aHumans
650 0 4 _aRegistries
_xstatistics & numerical data
650 0 4 _aUnited States
650 0 4 _aUnited States Food and Drug Administration
700 1 _aShopshear, Olivia M
700 1 _aJazic, Ina
700 1 _aUlrich, Jocelyn
700 1 _aFrancer, Jeffrey
773 0 _tBMJ open
_gvol. 7
_gno. 9
_gp. e015110
856 4 0 _uhttps://doi.org/10.1136/bmjopen-2016-015110
_zAvailable from publisher's website
999 _c27596682
_d27596682